The Study On The Influence Of Busuishengxue Granule To Bloodil-12 Receptor In Myelodyplastic Syndrome-Refractory Anemia

Objective:To observe the clinical effect of Busui Shengxue granule(BSSXG) in treating Myelodyplastic Syndrome-Refractory Anemia(MDS-RA),evaluate the expression of the blood IL-12 before and after treatment, and further discusse BSSXG to treat MDS-RA the clinical effect and to the IL-12 influence.Methods: Forty cases of MDS-RA were divided into two groups, twenty-five patients of experiment group were treated with BSSXG and fifteen of control were treated with ATRA. We observed the clinical effect of these forty patients treated with two groups. We explored ELISA to detect forty patients the expression of the blood IL-12 before and after treatment.Results: 1.BSSXG to MDS-RA can effectively improve anemia and hemorrhage symptom, and peripheral blood, discrease immature cells in peripheral blood and bone marrow,there is not difference between the experiment group and the control group(P>0.05); 2.The expression level of blood IL-12 in MDS patients was high, aftertreatment the expression level was descended.Conclusion: 1.There was abnormal expression of the blood IL-12 in MDS-RA patients; 2.It demonstrats that BSSXG can lower the level of negative factors for hematopoiesis regulation and there is no obvious difference between the experiment group and the control group(P>0.05); 3.BSSXG is effective to treat MDS-RA, and worthy of further study and development.